💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Bal Pharma Limited is a pharmaceutical company engaged in the manufacturing and selling of pharmaceutical products. The Company is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). It specializes in…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, fast-growing business, reasonably priced.
Bal Pharma is scored on the pharma / healthcare framework. It keeps a thin 2.0% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 4.88× reported profit. It throws off free cash worth 7.7% of its market value — a strong free-cash yield.
Over the last 3 years revenue compounded at 1%/yr and profit at 34%/yr. Book value has grown 9%/yr. Return on equity is a weak 7.6%. In the latest quarter profit fell 68% versus the prior quarter.
At 21× earnings, the stock sits at the 31st percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price implies ~8%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 18.08 | — | — |
| P/B | 1.59 | 4.11 | better |
| EV/EBITDA | 8.05 | 19.15 | better |
| ROE | 7.64 | — | — |
| ROCE | 9.18 | 6.87 | better |
| ROA | 1.93 | 1.26 | better |
| Quick Ratio | 0.59 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
1% CAGR — growing but slowly. Growth is accelerating — latest year outpaced the prior year's rate.
Profit is growing faster than revenue (34% vs 1%) — margin expansion is at work.
Operating margins have been stable around 2% — no major structural shift.
ROE at 8% — modest; the capital isn't working hard. Low variance across years — a predictable business that earns steadily on its equity base.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. 33% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
1 of 4 years had negative operating cash flow — profitability on paper may not translate to cash. Cash conversion at 4.9× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 6% sequentially — momentum is building.
Profit fell 68% QoQ — one-quarter drops can be noise, but a pattern matters.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 50.9% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.